A Comparison of the Prognostic Value of Early PSA Test-Based Variables Following External Beam Radiotherapy, With or Without Preceding Androgen Deprivation: Analysis of Data From the TROG 96.01 Randomized Trial-Reference-Cited by-同舟云学术

A Comparison of the Prognostic Value of Early PSA Test-Based Variables Following External Beam Radiotherapy, With or Without Preceding Androgen Deprivation: Analysis of Data From the TROG 96.01 Randomized Trial

Published:2011-02 Issue:2 Volume:79 Page:385-391
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Lamb David S.,Denham James W.,Joseph David,Matthews John,Atkinson Chris,Spry Nigel A.,Duchesne Gillian,Ebert Martin,Steigler Allison,Delahunt Brett,D'Este Catherine

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Radiation

Reference19 articles.

1. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer;Crawford;Urology,2009

2. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial;Denham;Lancet Oncol,2008

3. Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?;Denham;Cancer,2009

4. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer;Oesterling;JAMA,1993

5. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer;Gleave;Urology,1996

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute Toxicity and Early Prostate Specific Antigen Response After Two-Fraction Stereotactic Radiation Therapy for Localized Prostate Cancer Using Peri-Rectal Spacing – Initial Report of the SABR-Dual Trial;International Journal of Radiation Oncology*Biology*Physics;2024-07

2. Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer;Frontiers in Oncology;2023-10-17

3. 18F-DCFPyL PET/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy;European Journal of Nuclear Medicine and Molecular Imaging;2020-07-27

4. Long-Term Dynamics of Three Dimensional Telomere Profiles in Circulating Tumor Cells in High-Risk Prostate Cancer Patients Undergoing Androgen-Deprivation and Radiation Therapy;Cancers;2019-08-14

5. Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials;International Journal of Radiation Oncology*Biology*Physics;2019-08